MSD has joined fellow big pharmas in looking to redirect cash, as the drugmaker revealed plans to save $3bn annually by the end of 2027.

South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Despite being significantly lower than the 200% rate threatened by Trump, the deal is set to ramp up drug costs by billions.

Re-Vana Therapeutics has entered a partnership and licence agreement with Boehringer Ingelheim for the development of eye therapies.

Alfasigma is in discussions with the EMA and MHRA about Jyseleca for axSpA but has yet to reveal any plans for US submission.

The FDA has approved Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH) for the treatment of adults with GHD.

It has been a tumultuous two weeks for Sarepta; however, the FDA reauthorising US shipments of Elevidys will be a welcome development.

The US biopharma has planted roots in the UK’s biotech cluster as it bets on synthetic rescue to unlock new treatments for rare diseases.

The HS market across the 7MM is forecast to grow from $1.84bn in 2024 to $7.83bn in 2034, according to GlobalData.

A new report examines why linked data is essential to advancing healthcare and improving outcomes for patients.